Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navenibart in Hereditary Angioedema (ORBIT-EXPANSE)
NCT07204938Phase 3Enrolling by invitation
- Sponsor
- Astria Therapeutics
- Start
- Oct 2025
- Primary completion
- Jun 2031
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of navenibart in hereditary angioedema (HAE), sponsored by Astria Therapeutics. Started Oct 2025; status: enrolling by invitation.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT07204938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204938.